Medindia

X

DyCE(TM) (Dynamic Contrast Enhancement) Technology Now Part of CRi's Analysis Software Suite for the Popular Maestro(TM) in vivo Molecular Imaging System

Friday, March 21, 2008 General News J E 4
Advertisement
WOBURN, Mass., March 20 Cambridge Research &Instrumentation, Inc. (CRi) is shipping DyCE(TM) (Dynamic ContrastEnhancement), a new technology application, to users of the award-winningMaestro(TM) in vivo molecular imaging system. Customers can now generate all-optical anatomical images of mouse models in only a few minutes, saving timeand enabling better time-resolved images of molecular probe distribution.

CRi has an exclusive commercialization agreement with MassachusettsGeneral Hospital (MGH) for its DyCE application which received widespreadacclaim when introduced at the recent Society of Molecular Imaging/Academy ofMolecular Imaging joint conference for in vivo imaging. DyCE was also featuredin the cover article in Nature Photonics in August of 2007.

"DyCE is a quantum leap forward for optical imaging, poised torevolutionize in vivo fluorescence imaging," says James Mansfield, Director ofMultispectral Imaging Systems at CRi. "Our customers can now produceanatomical images in record time and also save significant money versusconventional means."

Anatomical images are produced using DyCE in the following way. A bolus ofan inert near-infrared dye (such as indocyanine green) is injected, and then atime-based series of data is collected. Using CRi's analysis software, thisdata set is interpreted to delineate most of the major organ systems, usingoptical imaging alone. This organ-specific imaging is possible, because organshave characteristic uptake or distribution patterns over time that can be'illuminated' by the dye passing through, distinguishing them from otherstructures.

These in vivo anatomical maps can be overlaid co-registered withsimultaneously acquired images of a targeted molecular probe to delineate themarker's specific anatomical and physical location at any time point in thestudy.

"CRi is uniquely positioned to commercialize DyCE capitalizing on thecombination of our advanced multispectral in vivo imaging systems and ourindustry-leading data analysis tools," explains George Abe, CRi's Presidentand CEO.

"We are pleased to partner with the Massachusetts General Hospital in thisendeavor and are excited to enable our customers to further advance theirsmall animal imaging capabilities", continued Abe.

CRi will be exhibiting the latest automated Maestro 2 system featuringDyCE along with CRi's cellular imaging solutions at the Annual Meeting of theAmerican Association for Cancer Research (AACR), April 12 to 16 (Booth 235).Attendees can make an appointment to meet with a sales or technicalrepresentative by e-mailing aacr@cri-inc.com or calling (Toll-Free US) 1-800-383-7924.

CRi is a Boston-based biomedical imaging company providing innovativeoptical imaging solutions to our customers for more than 20 years. Ourmultidisciplinary team is dedicated to working with our academic andcommercial customers to provide high-value solutions. We provide comprehensiveimaging and analysis solutions that enable the user to investigate andcharacterize biological phenotypes while preserving spatial context. CRi'sinnovative solutions encompass sub-cellular, cellular and whole animalapplications, and are being utilized around the world to enable breakthroughsin research, health and medicine.For more information visit our website at www.cri-inc.com or contact: Ross Nakatsuji CRi Marketing/Sales Group Leader 35-B Cabot Road, Woburn, MA 01801 USA (P) 1-781-935-9099, extension 177 (C) 1-781-405-4000 (E) rnakatsuji@cri-inc.com

SOURCE Cambridge Research & Instrumentation, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Perrigo Company Announces Launch of Clobetasol Pro...
S
Arthur J. Gallagher & Co. Acquires Healthcare Risk...